Efficacy studies (Meta-analyses) | Effectiveness studies | ||||||
---|---|---|---|---|---|---|---|
Study | Sánchez-Meca et al. [2] | McGuire et al. [3] | Valderhaug et al. [25] | Nakatani et al. [26] | Farrell et al. [27] | Torp et al. [28] | Current study |
Completers % | M = 91.4 (treatment group) | Range of means: 73 – 100 (treatment group) | 86.0 | Not available | 94.3 | 89.6 | 86.8 |
Mean reduction in CY-BOCS total score % | Not investigated | Not investigated | After 12 sessions: 60.6 | After 5–28 sessions: 51.8 | After 8–14 sessions: 61 | After 14 sessions: 52.9 (SD = 30.9) | After 12 sessions: 34.0 after 18–54 sessions: 68.8 |
Effect size on total OCD symptoms | Global: after M = 11.8 weeks: 1.71 | Clinician-rated: after 9–14 sessions: 1.21 | Clinician-rated: after 12 sessions: 3.52 | Clinician-rated: after 5–28 sessions: 2.32 | Clinician-rated: after 8–14 sessions: 2.12 | Clinician-rated: after 14 sessions: 1.62 | Clinician-rated: after 12 sessions: 1.52 after further 42 sessions: 1.72 child-rated: after 12 sessions: 0.42 after further 42 sessions: 0.52 parent-rated: after 12 sessions: 0.42 after further 42 sessions: 0.52 |
Remission criteria & rate % | Not investigated | Criteria: no consistent remission criteria among RCTs (e.g. CY-BOCS ≤ 10 or CY-BOCS ≤ 14) | Criteria: CY-BOCS ≤ 9 | Criteria: CY-BOCS ≤ 11 | Criteria: CY-BOCS ≤ 10 | Criteria: CY-BOCS ≤ 10 | Criteria: CY-BOCS ≤ 7 (CY-BOCS ≤ 10) |
Remission rate: after 9–14 sessions: 57 | Remission rate: after 12 sessions: 50 | Remission rate: after 5–28 sessions: 60 | Remission rate: after 8–14 sessions: 63 | Remission rate: after 14 sessions: 49.4 | Remission rate: after 12 sessions: 8.6 (16.7) after 18–54 sessions: 57.6 (57.6) | ||
Reliable change % based on CY-BOCS | Not investigated | Not investigated | Not investigated | Not investigated | After 8–14 sessions: 86 | After 14 sessions: 70.1 | After 12 sessions: 57.1 after 18–54 sessions: 87.9 |
Effects on comorbid symptoms | After M = 11.8 weeks: Anxiety: Global: ES = 0.61 (n = 6 studies) Depression: Global: ES = 0.41 (n = 6 studies) | Not investigated | Not investigated | Not investigated | After 8–14 sessions: Overall comorbid symptoms: Clinician-rated: 45% reduction in secondary diagnoses Anxiety: Child-rated: ES = 0.22, 0.42 Depression: Child-rated: ES = 0.32 | Not investigated | After 18–54 sessions: Overall comorbid symptoms: child-rated: ES = 0.42 parent-rated: ES = 0.62 Anxiety: child-rated: ES = 0.62 parent-rated: ES = 0.62 Depression: clinician-rated: ES = 0.52 child-rated: ES = 0.42 parent-rated: ES = 0.62 |
Effects on psychosocial impairment | Global: after M = 11.8 weeks: ES = 0.81 (n = 4 studies) | Not investigated | Child-rated: after 12 sessions: 49.6% mean reduction Parent-rated: after 12 sessions: 60.8% mean reduction | Not investigated | Child-rated: after 8–14 sessions: ES = 0.52 Parent-rated: after 8–14 sessions: ES = 0.52 | Not investigated | Child-rated: after 12 sessions: ES = 0.32 after further 42 sessions: ES = 0.32 Parent-rated: after 12 sessions: ES = 0.62 after further 42 sessions: ES = 0.62 |